Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.67 |
| ▸ | TNF | P01375 | 2/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650376 | 0.85 | CRBN (0.83) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL25650431 | 0.84 | CRBN (0.60) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL23292818 | 0.84 | CRBN (0.65) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL2051062 | 0.84 | CRBN (0.75) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL2049327 | 0.84 | CRBN (0.75) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL2049325 | 0.84 | CRBN (0.75) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL25650294 | 0.83 | CRBN (0.81) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL25650418 | 0.83 | CRBN (0.62) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL4941366 | 0.80 | CRBN (1.00) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL5958878 | 0.80 | CRBN (0.72) | CRBNTNFDDB1IKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716314-B2 | Isotopologues of thalidomide | CELGENE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CELGENE CORPORATION | 2012-03-15 | — | — | US | disclosed |
| EP-1710242-A1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha levels | CELGENE CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1308444-B1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha Levels | CELGENE CORP (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1308444-A1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha Levels | CELGENE CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1062214-B1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFA LEVELS | CELGENE CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5955476-A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5874448-A | DRUGS FOR REDUCING THE LEVEL OF TUMOR NECROSIS FACTOR, INCREASING ADENOSINE-3',5'CYCLIC MONOPHOSPHATE, INHIBITING PHOSPHODIESTERASE; TREATING BONE DISORDER, INFECTIONS, CANCER, IMMUNE DISEASE | CELGENE CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CDK4, FKBP8, FKBP1A | CRBN 475/4885TNF 2015/4885DDB1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.